DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

DSS, Inc. announced that Zoar Limited has filed a Form F-4 registration statement with the SEC in connection with Impact Biomedical's proposed business combination with Zoar. DSS is a significant stockholder of Impact Biomedical (NYSE American: IBO), and CEO Jason Grady characterized the filing as continued momentum that could ultimately create meaningful value for DSS and its shareholders.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.